Meeting Banner
Abstract #3738

Modification of tumour hypoxia with Atovaquone measured by CEST MRI

Kevin J Ray1, James Coates1, Rathi Puliyadi1, Thomas M Ashton1, Paul Kinchesh1, Sean Smart1, Michael A Chappell2, Geoff S Higgins1, and Nicola R Sibson1

1Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, United Kingdom, 2Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, United Kingdom

Tumours often have areas of hypoxia, which renders cancer cells resistant to many therapies. Recently the anti-malarial drug Atovaquone has been shown to modify the oxygen consumption rate of cancer cells, reducing tumour hypoxia. Non-invasive mapping of tumour hypoxia would be particularly useful for translation of these preclinical findings into a clinical environment. Here, we tested the hypothesis that CEST MRI could be used to visualise changes in tumour hypoxia.

This abstract and the presentation materials are available to members only; a login is required.

Join Here